[Ip-health] Hepatitis C Treatment Wins Approval, but Price Relief May Be Limited - NYTimes.com

Jamie Love james.love at keionline.org
Fri Dec 19 19:18:33 PST 2014


A new treatment for hepatitis C developed by AbbVie won approval from the
Food and Drug Administration on Friday, setting the stage for a marketing
battle with Gilead Sciences, whose two new drugs for the disease have drawn
an outcry about the high cost of medicines.

Insurers and state Medicaid programs have been eagerly awaiting the
approval of the AbbVie regimen, which is called Viekira Pak, hoping that
competition will drive down prices.

But price competition might be limited.

AbbVie said the wholesale price of Viekira Pak would be $83,319 for a
typical 12-week course of therapy. That is less than the $94,500 for 12
weeks of Gilead’s Harvoni, but probably not enough of a discount to allay
complaints about high prices.


More information about the Ip-health mailing list